Sandoz Negotiates Expanded RoW Rights to Vectura’s Asthma/COPD Drug VR315 – Genetic Engineering News


Stockopedia

Sandoz Negotiates Expanded RoW Rights to Vectura's Asthma/COPD Drug VR315
Genetic Engineering News
The Novartis generics business, Sandoz, negotiated expanded, rest-of-world (excluding the US) rights to Vectura's VR315 candidate combination therapy for asthma/COPD. Sandoz already holds European rights to the dry powder inhaler product.
Vectura Extends Novartis Deal For VR315 Lung DrugFox Business
VECTURA GROUP PLC : VR315 RoW License Agreement4-traders (press release)
Vectura signs up Sandoz for asthma drug in RoW; good results for ALK Abello The Pharma Letter
Stockopedia
all 9 news articles »

View full post on asthma – Google News

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.